Metrion Biosciences Ltd, a Cambridge, England, UK-based specialist ion channel contract research and drug discovery company, completed a funding round of undisclosed amount.
The new round was led by the recently launched o2h Ventures Therapeutics Fund, acting via Reyker Securities plc, and supported by existing shareholders.
The company will use the funds to support the broadening of its ion channel screening capabilities, and continued research into novel Kv1.3 inhibitors for the treatment of auto-immune conditions.
Led by Keith McCullagh, chairman, Metrion is a UK-based Contract Research Organization (CRO) focused on delivering a range of high quality ion channel drug discovery services. The company provides skilled electrophysiology screening services to support client medicinal chemistry optimisation programmes, CiPA compliant cardiac safety profiling assays, neuroscience assays and translational assays.